ストックスクリーナーアプリを入手
3.96
4.12%
-0.17
プレマーケット:
3.95
-0.010
-0.25%
前日終値:
$4.13
開ける：
$4.13
24時間の取引高:
5.03M
Relative Volume:
1.03
時価総額：
$793.34M
収益：
$314.00K
当期純損益:
$-40.23M
株価収益率:
-14.14
EPS:
-0.28
ネットキャッシュフロー:
$-84.71M
1週間 パフォーマンス:
-7.04%
1か月 パフォーマンス:
+51.15%
6か月 パフォーマンス:
+77.58%
1年 パフォーマンス:
+211.81%
1日の値動き範囲:
$3.871
$4.30
1週間の範囲:
$3.78
$4.30
52週間の値動き範囲:
$1.03
$4.40
Atai Life Sciences N V Stock (ATAI) Company Profile
ATAI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ATAI
Atai Life Sciences N V
|
3.96 | 876.15M | 314.00K | -40.23M | -84.71M | -0.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
374.46 | 93.98B | 11.42B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
435.00 | 57.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.94 | 59.67B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
638.90 | 40.50B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
289.75 | 34.26B | 3.81B | -644.79M | -669.77M | -6.24 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-29 | 開始されました | Oppenheimer | Outperform |
| 2024-11-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-04-03 | アップグレード | Maxim Group | Hold → Buy |
| 2022-11-01 | 開始されました | Loop Capital | Buy |
| 2021-11-30 | 開始されました | Maxim Group | Buy |
| 2021-11-11 | 開始されました | ROTH Capital | Buy |
| 2021-10-18 | 開始されました | H.C. Wainwright | Buy |
| 2021-09-01 | 開始されました | Jefferies | Buy |
| 2021-07-13 | 開始されました | Berenberg | Buy |
| 2021-07-13 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-13 | 開始されました | Cantor Fitzgerald | Buy |
| 2021-07-13 | 開始されました | Citigroup | Buy |
| 2021-07-13 | 開始されました | Cowen | Outperform |
| 2021-07-13 | 開始されました | Credit Suisse | Outperform |
| 2021-07-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2021-07-08 | 開始されました | Aegis Capital | Buy |
すべてを表示
Atai Life Sciences N V (ATAI) 最新ニュース
Atai Life Sciences N.V. Bounces Off Moving Average SupportConservative Long Term Growth Plans Under Review - metal.it
Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT - Insider Monkey
How volatile is Atai Life Sciences N.V. stock compared to the marketAchieve consistent profits with expert advice - Jammu Links News
Atai Life Sciences N.V. Stock Analysis and ForecastFree Stock Market Return Analysis - Jammu Links News
What are analysts’ price targets for Atai Life Sciences N.V. in the next 12 monthsBoost your returns with professional guidance - Jammu Links News
How many analysts rate Atai Life Sciences N.V. as a “Buy”Dynamic profit expansion - Jammu Links News
What are the latest earnings results for Atai Life Sciences N.V.Maximize your gains with professional insights - Jammu Links News
What drives Atai Life Sciences N.V. stock priceGet timely advice on market trends - Jammu Links News
Does Atai Life Sciences N.V. stock perform well during market downturnsTrack top-performing stocks effortlessly - Jammu Links News
How does Atai Life Sciences N.V. generate profit in a changing economyFree Trend-Following Techniques - Jammu Links News
What is the risk reward ratio of investing in Atai Life Sciences N.V. stockDiscover breakthrough stocks with expert help - jammulinksnews.com
How does Atai Life Sciences N.V. compare to its industry peersSky-high return potential - Jammu Links News
H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 - Insider Monkey
AbbVie in Talks to Acquire Gilgamesh in $1 Billion Deal - Bloomberg.com
H.C. Wainwright raises atai Life Sciences stock price target to $15 on BPL-003 potential - Investing.com Nigeria
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Published on: 2025-07-30 03:07:04 - metal.it
What makes Atai Life Sciences N.V. stock price move sharplySwing Setup With Technical Confirmation Explained - metal.it
This Atai Life Sciences Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday - 富途牛牛
How did ATAI's revenue and expenses shift in Q4 2024? - AInvest
Oppenheimer initiates coverage on ATAI Life Sciences with Outperform rating, $14 PT. - AInvest
Oppenheimer initiates atai Life Sciences stock with Outperform rating By Investing.com - Investing.com Nigeria
Oppenheimer initiates atai Life Sciences stock with Outperform rating - Investing.com
Published on: 2025-07-29 09:29:36 - metal.it
Atai: Inidascamine Trial Failure Doesn't Matter In Main Psychedelic Pipeline Focus (ATAI) - Seeking Alpha
ATAI Life Sciences Surges Amidst Market Uncertainty - StocksToTrade
Why Is ATAI Life Sciences Stock Trading Lower On Monday? - inkl
Published on: 2025-07-28 17:17:36 - beatles.ru
ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News - Yahoo Finance
ATAI Life Sciences, Revvity And Other Big Stocks Moving Lower In Monday's Pre-Market Session - 富途牛牛
Why Celcuity Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket - Benzinga
Nucor, Waste Management And 3 Stocks To Watch Heading Into Monday - Benzinga
What is Atai Life Sciences N.V. company’s growth strategyGet insider insights into market trends - Jammu Links News
What are Atai Life Sciences N.V. company’s key revenue driversExceptional stock performance - Jammu Links News
Why Atai Life Sciences N.V. stock attracts strong analyst attentionFree Access to Community - metal.it
Atai Life Sciences (ATAI) Shares Drop 12% After Schizophrenia Dr - GuruFocus
Atai Life Sciences shares fall 14.29% after-hours as schizophrenia drug fails to meet main endpoint. - AInvest
Atai Life Sciences down 12% after hours on mid-stage failure of schizophrenia asset - Seeking Alpha
Published on: 2025-07-26 00:30:53 - PrintWeekIndia
ATAI Life Sciences stock falls after Recognify’s CIAS drug misses endpoint - Investing.com UK
Clinical Trial Reveals Promising Signals for New Schizophrenia Cognitive Drug Despite Missed Endpoint - Stock Titan
Canaccord Increases Atai Life Sciences (ATAI) PT, Keeps Buy Rating - Insider Monkey
10 Best Performing Penny Stocks So Far in 2025 - Insider Monkey
Is Atai Life Sciences N.V. a good long term investmentBreakout profit opportunities - PrintWeekIndia
Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)’s Price Target To $12, Maintains Buy Rating - MSN
What analysts say about Atai Life Sciences N.V. stockMassive wealth growth - Autocar Professional
Atai Life Sciences N V (ATAI) 財務データ
収益
当期純利益
現金流量
EPS
1.02%
3.70%
大文字化:
|
ボリューム (24 時間):